Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-2.3.1-1 | Award Amount: 7.69M | Year: 2009
Multi-drug-resistant bacterial infections are increasing at an alarming pace in both developing and developed countries and in both community and nosocomial settings. The few antimicrobial agents that have been launched during the last decade (e.g. linezolid, daptomycin) have a good activity against Gram-positive bacteria. However, multi-drug-resistant bacteria are often found among the Gram-negative group. To tackle this problem, the AntiPathoGN project proposes a novel strategy for the discovery of new antimicrobial drug targets in a number of Gram-negative bacteria. This strategy is based on a comparative, system-level analysis of molecular processes involved in pathogenicity, drug resistance, cell division and/or growth of selected pathogenic Gram-negative bacteria through a combination of computational biology, interactome discovery, in-vivo protein-blocking and structural biology techniques. This comparative analysis, at one organization level above genomics, shall permit the discovery of new potential drug targets, relevant to both species-specific and broad-spectrum antimicrobial strategies. In addition, the AntiPathoGN project will pursue the identification of novel antibacterial compounds acting against previously validated targets by screening purpose-specific libraries of products derived from natural resources and from synthetic compounds. An important aspect of the project is that more than one approach is planned for the key objectives of target identification, target validation, target characterisation, and hit finding. The AntiPathoGN consortium is composed of 1 university bringing expertises in computational biology and microbiology, 3 research centres with expertises in computational and experimental interactomics, structural biology and clinical microbiology, and 7 SMEs with records on recombinant-antibody technology, structural biology, drug discovery and clinical research. The AntiPathoGN project fully addresses topic HEALTH-2007-2.3.1-1.
Intermed Discovery Gmbh | Date: 2011-06-03
The invention relates to cyclopentabenzofuran derivatives for the treatment and/or prophylaxis of angiogenesis-related disorders.
InterMed Discovery GmbH | Date: 2012-12-12
The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. The compounds have the formula IR is a carbohydrate moiety bound via one of its carbon atoms to the binding oxygen,and/or a physiologically, especially pharmaceutically or nutraceutically or cosmetically, acceptable salt thereof, or an ester thereof,as such or in the form of a composition,where the compound may be present in open chain form and/or in the form of a lactone (Fig. 1).
InterMed Discovery GmbH | Date: 2011-11-30
The invention relates to a process for producing one or more polyunsaturated fatty acids by means of heterologous gene expression, the process comprising the steps:(i) providing a production organism which comprises a gene cluster encoding a polyunsaturated fatty acid biosynthetic pathway, said gene cluster- being derived from a source organism which differs from the production organism; and- encompassing a subsequence ER encoding an enoylreductase and a subsequence AT encoding an acyltransferase, wherein the subsequence AT is located downstream with respect to the subsequence ER;(ii) growing the production organism of step (i) in the presence of a fermentable carbon source whereby one or more polyunsaturated fatty acids are produced; and(iii) optionally, recovering the one or more polyunsaturated fatty acids.
Intermed Discovery Gmbh | Date: 2012-11-19
The invention relates to an extract and/or one or more natural compounds from plants or parts of plants, respectively, from a genus selected from Schisandra, Illicium, Kadsura, Steganotaenia or Magnolia, for the regulation of body weight, fat loss, and/or management of obesity, in humans or in animals, methods and uses of the same and to the use of the same or mixtures in the manufacture of a pharmaceutical or nutraceutical formulation. The above can further be used to reduce one or more adverse metabolic parameters in a subject. The invention relates also to said extract and/or compound(s) in the treatment or in the preparation of a medicament for treatment of obesity, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s), which are useful in the regulation of body weight and/or fat loss and/or for the management of obesity.
InterMed Discovery GmbH | Date: 2012-06-27
The invention relates to the use, or methods (especially with regard to animals, especially human, that are in need of such treatment) comprising the use, respectively, of an extract and/or especially one or more natural spiro triterpenoids and derivatives thereof, especially from the blazeispirol family, obtainable from Agaricus species, alone or as supplement, as active ingredient in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor, either in humans or in other mammals, and/or to the use of said extract and/or natural compound(s) or mixtures for the treatment of said disease, disorder or condition, as well as corresponding methods of treatment, or their use in the manufacture of a pharmaceutical or nutraceutical formulation for said treatment. The invention relates also to said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disorder, disorder or condition, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment. They can also be used for non-therapeutic, e.g. cosmetic, purposes only.
Intermed Discovery GmbH | Date: 2011-11-11
Compounds obtainable from plants, e.g. of the genus Eucalyptus, or from microorganisms are shown to be useful as CNS activity modulators useful e.g. in the treatment of depression, for lifting mood and/or for increasing behavioural initiative and the like. This use and related aspects form embodiments of the invention. Also compounds as such are presented. The compounds useful are acylphloroglucine derivatives of the formula I, wherein the substituents are as defined in the description.
InterMed Discovery GmbH | Date: 2011-07-20
Intermed Discovery Gmbh | Date: 2011-01-13
A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeuticincluding prophylactictreatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.
Intermed Discovery GMBH | Date: 2011-12-08
The invention relates to compositions and methods (with regard to animals and humans) for utilizing an extract and/or one or more natural spiro triterpenoids and derivatives thereof alone or as a supplement. Certain materials utilized are from the blazeispirol family, obtainable from Agaricus species. Treatments include the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor, as well as corresponding methods of treatment, the manufacture of a pharmaceutical and nutraceutical formulation for said treatment. The invention also relates to the use of the extract and compound(s) in the treatment or in the preparation of a medicament (e.g. a nutraceutical) for the prophylactic and/or therapeutic treatments, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations described herein which are useful in prophylactic and therapeutic treatments. They can also be used for non-therapeutic, e.g. cosmetic, purposes.